Remove world
article thumbnail

World IP Day 2023: Celebrating women leaders in innovation

PhRMA

Today PhRMA joins with innovators around the globe to recognize World IP Day and celebrate biopharmaceutical innovators who dedicate their lives to bringing new treatments and cures to patients.

235
235
article thumbnail

AI-powered real-world evidence generation for biotechs

pharmaphorum

Discover how AI-powered real-world evidence generation is revolutionising the biotech industry, providing valuable insights for biopharma companies to make informed decisions. Learn more about the impact of RWD on biotechs.

113
113
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

What you should know about real-world evidence and drug development

PhRMA

to discuss using real-world data and real-world evidence for regulatory decision-making. Recently, industry leaders, regulators, academics, data partners, and patient advocates gathered in Washington, D.C.,

FDA 214
article thumbnail

Building the patient experience into observational studies produces stronger real-world evidence

pharmaphorum

Incorporating the patient experience into observational studies can enhance the quality of real-world evidence gathered. Learn how patient-centred approaches can lead to stronger research outcomes.

118
118
article thumbnail

Tymlos outperforms teriparatide in real-world fracture analysis

Pharmaceutical Technology

Radius Pharmaceuticals presented real-world evidence at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases on 12 April 2024, demonstrating that Tymlos therapy resulted in a lower incidence of hip and nonvertebral fractures compared to teriparatide therapy in women with osteoporosis aged 50 and older.

52
article thumbnail

2024 Pipeline Report: First-World Focus

PharmExec

Pharm Exec’s 19th annual report on the trends of the day in drug development examines the surging investment in new treatments and advances for so-called “first-world” conditions, capturing the landscape of five expanding therapeutic areas: weight loss, osteoarthritis, Alzheimer’s disease, COPD, and psychedelics.

110
110
article thumbnail

Roche gets first world okay for PNH drug crovalimab

pharmaphorum

China has become the first country in the world to approve Roche’s anti-complement C5 antibody crovalimab, the only treatment for the rare disorder paroxysmal nocturnal haemoglobinuria (PNH) that can be given by subcutaneous injection.

108
108